1. Biomarkers in MS and NMOSD
  2. Molecular Neuropathology and Neuroimaging
  3. Rehabilitation and Regeneration
  4. Current and Emerging Therapeutic Approaches


Wednesday, 13 November 2019
Royal Pavilion Ballroom, Level 1
13:30-15:00 European Charcot Foundation Symposium
B-Cells Treatment
Chairperson: Hans-Peter Hartung (Germany) & Kazuo Fujihara (Japan)
1. B-Cells in Multiple Sclerosis and NMOSD: Evidence from Pathology
– Hans Lassmann (Austria)
2. Are B-Cells the Key Target in Relapsing Multiple Sclerosis?
– Hans-Peter Hartung (Germany)
3. B Cells in Neuromyelitis Optica Spectrum Disorder
– Ho Jin Kim (Republic of Korea)
4. Anti B-Cell Therapies: Now and Tomorrow
– Ludwig Kappos (Switzerland)
15:00-15:30 Coffee Break
15:30-15:45 Opening Ceremony
1. Welcome Address by the Chairman, 2019 Local Organising Committee
– Kevin Tan (Singapore)
2. Opening Address by the President, PACTRIMS
– Kazuo Fujihara (Japan)
3. Special Remarks by the Director of Medical Services, Ministry of Health (Singapore)
– Benjamin Ong (Singapore)
15:45-17:15 Opening Lecture Series
Opening Lecture-1
Chairperson: Fu-Dong Shi (China)
L-1 Biological Basis of MS Severity
– Bibiana Bielekova (USA)
Opening Lecture-2
Chairperson: Michael Barnett (Australia)
L-2 High Intensity Therapy in Multiple Sclerosis: Why, When and How
– Heinz Wiendl (Germany)
17:15-17:30 Coffee Break
17:30-19:00 Novartis Sponsored Symposium
Perspectives on Personalized Medicine for Multiple Sclerosis
19:30-21:00 Welcome Reception @ Paterson, Level 3, Regent Singapore


Thursday, 14 November 2019
Royal Pavilion Ballroom, Level 1
08:30-10:00 Viela Bio Sponsored Symposium
The Landscape of Treatment of NMOSD – A Sea Change
10:00-10:30 Coffee Break
10:30-11:50 Oral Presentation-1
Clinical Neurology Session
Chairperson: Stephen Reddel (Australia) & Byoung-Joon Kim (Republic of Korea)
O-1 Alemtuzumab Maintains Efficacy on Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, Over 9 Years in RRMS Patients: CAREMS II Follow-up (TOPAZ Study)
– Giancarlo Comi (Italy)
O-2 Reduction in 48-Week Confirmed Disability Progression After 5.5 Years of Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis [Encore]
– Bruce Taylor (Australia)
O-3 The N-MOmentum Study–A Randomised, Placebo-Controlled, Double-Blind Trial of Inebilizumab for Neuromyelitis Optica Spectrum Disorder: Randomised Controlled Period and Open-label Extension Results
– Ho Jin Kim (Republic of Korea)
O-4 Efficacy and Safety of Eculizumab in Asian Patients With Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder: Subgroup Analysis From the Phase 3 PREVENT Study
– Ho Jin Kim (Republic of Korea)
O-5 Efficacy of Satralizumab (SA237) in Subgroups of Patients in SAkuraSky: A Phase III Double-Blind, Placebo-Controlled, Add-On Study in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
– Takashi Yamamura (Japan)
O-6 Tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorders (TANGO): a head-to-head comparative study
– Fu-Dong Shi (China)
11:50-12:50 Lunch @ Basilico, Level 2 & Nassim, Level 3, & Poster Viewing
12:50-14:50 Symposium-1
Molecular Neuropathology and Neuroimaging
Chairperson: Kevin Tan (Singapore) & Yaou Liu (China)
L-3 Molecular Neuropathology of Multiple Sclerosis
– Hans Lassmann (Austria)
L-4 Glial Pathology of Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders; Insight from Human Pathology and Genetics
– Katsuhisa Masaki (Japan)
L-5 Imaging Remyelination in Multiple Sclerosis: A Validated Biomarker of Lesion Repair?
– Cornelia Laule (Canada)
L-6 B Cells and Regulatory Plasma Cells in CNS Inflammation and Autoimmunity
– Simon Fillatreau (France)
14:50-15:50 Coffee Break & Poster Review
15:50-17:10 Plenary Lectures
Rehabilitation and Regeneration for Demyelinating Diseases
Plenary Lecture-3
Chairperson: Ho Jin Kim (Republic of Korea)
L-12 Rehabilitation of MS: Neuroplasticity and Neuroregeneration vs Compensation and Coping
– Alan Thompson (UK)
Plenary Lecture-4
Chairperson: William Carroll (Australia)
L-13 Neuro-repair in Progressive MS: Fact versus Fiction
– Hans-Peter Hartung (Germany)
17:10-17:30 Coffee Break
17:30-19:00 Eisai Sponsored Symposium
Evolving Paradigms in MS Disease Management: A Decade of Change
19:30-23:00 Presidential Dinner @ LeVeL33


Thursday, 14 November 2019
Paterson, Level 3 (Breakout Session)
10:30-11:50 Oral Presentation-2
Basic Science Session
Chairperson: Wei Qiu (China) & Todd Hardy (Australia)
O-7 Serum Neurofilament Light Chain Levels Among Patients With Clinically Isolted Syndrome
– Marzena Pedrini (Australia)
O-8 Cellular Immunity in Central Nervous System During Acute Flare-ups in Patients with Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorders
– Makoto Matsui (Japan)
O-9 Increase of Naïve B Cells M2 Macrophages and Reduction of Memory B/T Cells During Immune Repopulation at 96 Weeks in CLARITY Assessed by Immune Cell Deconvolution
– Giovannoni Gavin (UK)
O-10 KCNMA1 is associated with the disability and transverse myelitis of neuromyelitis optica spectrum disorders: a genome-wide association study in Japanese.
– Takuya Matsushita (Japan)
O-11 Elevated Serum Glial Fibrillary Acidic Protein (sGFAP) is Associated With Increased Risk of Neuromyelitis Optica Spectrum Disorder Attacks in the N-Momentum Randomized, Masked, Placebo-Controlled Clinical Trial of Inebilizumab
– Orhan Aktas (Germany)
O-12 Distinct distribution pattern of microglia and macrophages in concentric lesions of Baló’s disease and neuromyelitis optica spectrum disorders: with special reference to lamellar configuration
– Katsuhisa Masaki (Japan)
11:50-12:50 Lunch @ Basilico, Level 2 & Nassim, Level 3, & Poster Viewing
12:50-15:20 Symposium-2
Basic Immunology in MS and NMOSD
Chairperson: Ichiro Nakashima (Japan)
L-7 Pathogenic Function of Bystander-activated T Cells in Autoimmune Encephalomyelitis
– Je-min Choi (Republic of Korea)
L-8 B Cells in MS
– Yusei Miyazaki (Japan)
L-9 Biomarkers for MS/NMOSD
– Jiraporn Jitprapaikulsan (Thailand)
L-10 Gut Immune Cells in MS
– Anne-Katrin Proebstel (Switzerland)
L-11 Gut Microbiome in Autoimmune CNS Disorders: Insights from the Study of NMOSD Patients of Indian Origin
– Lekha Pandit (India)
15:20-15:40 Coffee Break & Poster Review
15:40-17:10 Issues in MS and a Patient-support Activity Session


Friday, 15 November 2019
Royal Pavilion Ballroom, Level 1
08:30-10:00 Alexion Sponsored Symposium
The Cascade Effect: The Role of Complement in Neuroimmunology and NMOSD
10:00-10:30 Coffee Break & Poster Review
10:30-12:30 Symposium-3
Current and Emerging Therapeutic Approaches
Chairperson: Sean Riminton (Australia) & Byung-Jo Kim (Republic of Korea)
L-14 Present and Future of B Cell Targeting Therapy
– Ludwig Kappos (Switzerland)
L-15 Immune Reconstitution Following DMT: The Devil Is In The Detail
– Jennifer Massey (Australia)
L-16 Defining B-Cell Subpopulations in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD): Implications for B Cell-Targeted Therapy
– Fu-Dong Shi (China)
L-17 Neuromyelitis Optica Spectrum Disorders: Treatment Paradigms in 2020 and Beyond
– Takashi Yamamura (Japan)
12:30-12:40 Closing and Award Ceremony
1. Award Ceremony
– Fu-Dong Shi (China)
2. Closing Remarks by the Vice President, PACTRIMS
– Ho Jin Kim (Republic of Korea)


Friday, 15 November 2019
Paterson, Level 3 (Breakout Session)
10:30-12:30 Symposium-4
Biomarkers and Diagnosis in MS and NMOSD
Chairperson: Allan Kermode (Australia) & Jin Nakahara (Japan)
L-18 Diagnostic Use of Metabolomics in Multiple Sclerosis and Its Mimics
– Tianrong Yeo (UK/Singapore)
L-19 The Eyes Have It: A Clinician’s Window on Inflammatory Brain Disease
– Ari Green (USA)
L-20 Lumpers and Splitters in NMOSD: Does It Matter?
– Kazuo Fujihara (Japan)
L-21 Novel Biomarkers for NMOSD
– Kuo-Hsuan Chang (Taiwan)


*subject to change